Close Menu

NEW YORK – Singapore-based Lucence Diagnostics and China's MEDx (Suzhou) Translational Medicine announced on Wednesday a strategic partnership aimed at cancer in China.

Under the agreement, the firms will codevelop companion diagnostic tests for PD-L1 rearrangement to be used with anti-PD1/PD-L1 cancer immunotherapies. Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.